Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.178570 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Stephanie Pain und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université de Poitiers, INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC U-1084, 86073, Poitiers, France; Service de Pharmacolo…. Hauptthemen laut MEDLINE: Alkaloids, Behavior, Animal, Substance-Related Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Catalonia Agency for Administration of University and Research Grants, Directorate-General for Justice, Agencia Estatal de Investigación.
Abstract (Originalsprache)
Synthetic cathinones constitute a major class of New Psychoactive Substances (NPS) with significant abuse potential. Within this class, 3F-N-ethylbuphedrone (3F-NEB or 2-(ethylamino)-1-(3-fluorophenyl)butan-1-one), a novel N-ethyl buphedrone derivative, has recently emerged in recreational drug markets. However, its pharmacological properties and abuse liability remain uncharacterized. The present study aimed to evaluate the neurochemical mechanisms and behavioral effects of 3F-NEB to assess its potential for abuse and addiction. To this end, we conducted in vitro monoamine uptake inhibition assays and in mice we performed locomotor activity and conditioned place preference tests. In rats, we conducted in vivo microdialysis in the nucleus accumbens, intravenous self-administration, and assessed neuroadaptive changes by ΔFosB immunohistochemistry following chronic self-administration. Our results demonstrate that 3F-NEB acts as a potent dopamine transporter (DAT) inhibitor, with more than 100-fold selectivity over the serotonin transporter (SERT). Acute administration (3 mg/kg) rapidly increased extracellular dopamine levels in the nucleus accumbens of rats. At the behavioral level, 3F-NEB induced dose-dependent locomotor increases (10-30 mg/kg), with anxiety-like effects at the highest doses, and conditioned place preference at all tested doses (3-30 mg/kg) in mice. 3F-NEB was readily self-administered by rats under both fixed-ratio and progressive-ratio schedules. Furthermore, chronic self-administration significantly increased ΔFosB expression in dorsomedial and dorsolateral striatum, mirroring patterns observed with methamphetamine. Taken together, these results demonstrate that 3F-NEB exhibits potent dopaminergic activity and high abuse liability through selective dopamine transporter inhibition. The compound's robust reinforcing properties and induction of addiction-related molecular adaptations suggest significant public health risks warranting immediate regulatory control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Poitiers, INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC U-1084, 86073, Poitiers, France; Service de Pharmacologie Clinique et Vigilances, CHU de Poitiers, Poitiers, France.
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, Universitat de Barcelona, 08028, Barcelona, Spain.
- Université de Poitiers, INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC U-1084, 86073, Poitiers, France.
- Chemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
- Pronexus Analytical AB, Grindstuvägen 44, Bromma, 167 33, Stockholm, Sweden.
- Université de Poitiers, INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC U-1084, 86073, Poitiers, France. Electronic address: marcello.solinas@univ-poitiers.fr.
Förderung
- Government of Catalonia Agency for Administration of University and Research Grants
- Directorate-General for Justice
- Agencia Estatal de Investigación
- Université de Poitiers
- European Commission
- Generalitat de Catalunya
- Ministerio de Ciencia, Innovación y Universidades
- Institut National de la Santé et de la Recherche Médicale
Zitieren
APA
Pain, S., Nadal-Gratacós, N., De Macedo, M., Lardeux, V., Mata, S., Puigseslloses, P., Wang, F. H., Källsten, L., Pubill, D., Berzosa, X., Kehr, J., Camarasa, J., Escubedo, E., López-Arnau, R., Thiriet, N., & Solinas, M. (2026). Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178570
Vancouver
Pain S, Nadal-Gratacós N, De Macedo M, Lardeux V, Mata S, Puigseslloses P, et al. Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178570
BibTeX
@article{Pain2026,
author = {Pain, Stephanie and Nadal-Gratacós, Núria and De Macedo, Morgane and Lardeux, Virginie and Mata, Sandra and Puigseslloses, Pol and Wang, Fu-Hua and Källsten, Liselott and Pubill, David and Berzosa, Xavier and Kehr, Jan and Camarasa, Jorge and Escubedo, Elena and López-Arnau, Raul and Thiriet, Nathalie and Solinas, Marcello},
title = {Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.178570}
}
EUVIMED